
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+1
ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP) concept and AMPLIVANTtechnology. SLPimmunotherapies are designed to fully harness and direct the bodys own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLPlead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810, Libtayo), a PD-1 (programmed cell death protein 1) antibody in development by Regeneron, which was...
Immunotherapy,persistant viral infections,oncology,cancer,synthetic long peptides,and t cell activation
Isa pharmaceuticals operates in the Biotechnology research industry.
Isa pharmaceuticals's revenue is 11m - 100m
Isa pharmaceuticals has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.